- BioVaxys Technology (BIOV) has closed the first tranche of a non-brokered private placement for gross proceeds of $200,000
- The company issued 2,000,000 units at $0.10 per unit
- Gross proceeds from the offering will total up to $1,000,000
- BioVaxys Technology Corp is a clinical-stage biopharma company
- BioVaxys Technology Corp. (BIOV) opened trading at C$0.105
BioVaxys Technology (BIOV) has closed the first tranche of a non-brokered private placement for gross proceeds of $200,000.
The company issued 2,000,000 units at $0.10 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant is exercisable for one additional common share for a period of 48 months.
Gross proceeds from the private placement will total approximately $1,000,000. The second tranche is expected to close within the next two weeks.
All securities issued are subject to a statutory four-month hold period.
Net proceeds from the private placement will be used as working capital.
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumour types.
BioVaxys Technology Corp. (BIOV) opened trading at C$0.105.
